Latest Annual Reports
by Mike Gee
12 June 2026









































ArriVent BioPharma, Inc.
REVENUE
N/A
INCOME
-$166,308,000
-106.62%
EMPLOYEES
N/A
CUSTOMERS
N/A
Clinical-stage company with substantial research and development spending, no reported product revenue in 2025, and net losses of $166,308,000 in 2025 and $80,488,000 in 2024.
View Company PageFiled: 2026-03-05
A.K.A. BRANDS HOLDING CORP.
REVENUE
$600,208,000
4.44%
INCOME
-$31,434,000
-20.95%
EMPLOYEES
1,650
CUSTOMERS
4,200,000
a.k.a. Brands Holding Corp. is a portfolio company that owns and operates next-generation fashion brands (Princess Polly, Culture Kings, Petal & Pup, mnml) using a data-driven, omnichannel approach combining digital-first sales with selective stores and wholesale partnerships.
View Company PageFiled: 2026-03-05
Bowman Consulting Group Ltd.
REVENUE
$490,017,000
14.88%
INCOME
$12,849,000
323.50%
EMPLOYEES
2,300
CUSTOMERS
N/A
Bowman is a publicly traded professional services firm delivering integrated engineering, technical consulting and program management services for the built environment across the United States.
View Company PageFiled: 2026-03-05
Amalgamated Financial Corp.
REVENUE
$328,724,000
4.14%
INCOME
$104,447,000
-1.87%
EMPLOYEES
450
CUSTOMERS
1,500
Amalgamated Financial Corp. is a Delaware public benefit holding company for Amalgamated Bank that markets itself as "America’s Socially Responsible Bank," focused on impact banking, mission-aligned lending, trust and investment management, and ESG/climate finance.
View Company PageFiled: 2026-03-05
Aligos Therapeutics, Inc.
REVENUE
$2,186,000
-44.59%
INCOME
-$24,193,000
81.56%
EMPLOYEES
82
CUSTOMERS
N/A
Clinical-stage biotechnology company developing small-molecule and oligonucleotide therapeutics for liver diseases (HBV, MASH/obesity) and viral infections (pan-coronavirus), with in-house CMC and discovery capabilities and multiple pre-commercial Phase 2 programs.
View Company PageFiled: 2026-03-05
Camp4 Therapeutics Corp
REVENUE
N/A
INCOME
-$80,400,000
-55.24%
EMPLOYEES
N/A
CUSTOMERS
N/A
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting antisense oligonucleotide therapies to upregulate gene expression for haploinsufficient CNS genetic diseases, with lead candidate CMP-002 for SYNGAP1-related developmental and epileptic encephalopathy.
View Company PageFiled: 2026-03-05
Bioventus Inc.
REVENUE
$568,087,000
-0.91%
INCOME
$27,274,000
157.97%
EMPLOYEES
N/A
CUSTOMERS
N/A
Global medical device company specializing in treatments and devices for musculoskeletal pain and injury recovery across Pain Treatments, Surgical Solutions, and Restorative Therapies, with US and International reporting segments.
View Company PageFiled: 2026-03-05
Blue Owl Capital Corp II
REVENUE
$195,915,000
-23.73%
INCOME
$24,070,000
-70.63%
EMPLOYEES
N/A
CUSTOMERS
N/A
Blue Owl Capital Corporation II is a closed-end, externally managed business development company that primarily originates and invests in debt (with selective equity) in U.S. middle-market companies to generate current income and secondary capital appreciation.
View Company PageFiled: 2026-03-05
CPI Card Group Inc.
REVENUE
$543,534,000
13.09%
INCOME
$14,950,000
-23.42%
EMPLOYEES
N/A
CUSTOMERS
2,000
CPI Card Group Inc. is a U.S.-focused payments technology company that provides end-to-end physical and digital payment card production, personalization, fulfillment and related secure services for financial institutions, processors, fintechs and prepaid program managers.
View Company PageFiled: 2026-03-05
Atea Pharmaceuticals, Inc.
REVENUE
N/A
INCOME
-$158,349,000
5.96%
EMPLOYEES
55
CUSTOMERS
N/A
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company developing oral nucleos(t)ide-based antivirals—primarily the HCV regimen bemnifosbuvir+ruzasvir and HEV candidate AT-587—targeting single-stranded RNA viruses.
View Company PageFiled: 2026-03-05
ADIAL PHARMACEUTICALS, INC.
REVENUE
N/A
INCOME
-$7,977,171
39.56%
EMPLOYEES
6
CUSTOMERS
N/A
Clinical-stage biopharmaceutical company developing AD04 (ondansetron) for genotype-guided treatment of Alcohol Use Disorder, paired with a companion diagnostic.
View Company PageFiled: 2026-03-05
Ambiq Micro, Inc.
REVENUE
$72,514,000
-4.67%
INCOME
-$36,500,000
7.97%
EMPLOYEES
202
CUSTOMERS
200
Ambiq is a public fabless semiconductor company that designs ultra-low-power SoCs and supporting software using its SPOT sub-threshold/near-threshold platform for energy-efficient edge AI compute.
View Company Page